TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of participants negative for influenza A by Respirio Flu Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants negative for influenza A by eLab Flu Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 3D-STI measurement indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of expression of microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Procoagulant activity of microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Assessment of post-zoster neuralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection rate of embedded ODD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of rater's comparisons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak and Mean Vasoactive-Ventilation-Renal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peak and Mean Vasoactive Inotrope scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline maximum vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plan quality of the MRI guided radiotherapy vs. conventional linac radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of SBRT delivery by the MRI-guided tri-60Co teletherapy system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of real-time image guidance provided by the tri-60Co system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration after a single dose (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from zero to the time of the last quantifiable concentration after a single (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from zero to infinity after a single dose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dimensions of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: clinical improvement in dry eye measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP levels in CD4+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of inappropriate hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of clinical risk factors for colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of biological risk factors for colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetics of PF-04457845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of PF-04457845
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of distribution of first compartment (V1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance from first to second compartment (Q1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of second compartment (V1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss maintenance efficacy (>5% and >10%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acknowledgment of elevated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Any Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Effect on recurrent laryngeal nerve monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of progression of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Brain response to pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Weekly Average Total Number of Cataplexy Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference of energy intake (kcal) in meals containing eggs vs meals without eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference of blood glucose levels compared between different test breakfasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference of insulin levels compared between different test breakfasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Femoral BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Change in haemoglobin (Hb) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antishivering effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) - Percentage of Participants With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Standard deviation of normal to normal RR-interval (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Root mean square of successive RR-interval differences (RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low frequency power (LF-power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High frequency power (HF-power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LF-power/HF-power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complications/adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum CC16 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Negative Symptom Scale (BNSS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Percent Change in Target Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Rating Scale Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait speed in cm/second
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Hoehn and Yahr staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of high titer, low titer and transient Factor VIII (FVIII) inhibitors developed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number and type of other serious and non-serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: re-craniotomy rate
Endpoint domain: Adverse events/effects
Primary endpoint: Boston Bowel Preparation Scale (BBPS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean change of area of neovascularization of the disc (NVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: change of area of neovascularization elsewhere in the retina (NVE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: regression of total area of neovascularization (NVD+NVE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time from evaluation to waitlisting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of pre-transplant evaluation completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in body weight index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility Outcome
Endpoint domain: Resource use
Primary endpoint: Number of subjects who develop oliguria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: delayed bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients Received Dydrogesterone Therapy Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Regular Menstrual Cycles During Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function/Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Survivorship of the study device
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With Any Antigen-Specific Cancer Immunotherapeutic (ASCI) Related Grade 3/4 Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: The Rate of Objective Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: monocyte CRP production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukocyte mRNA expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of Xpert Bladder Cancer Monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impaired mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Pain Relief Score Over the First 6 Hours (TOPAR6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended MTD
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients who consent to be randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective Response Rate (ORR) in participants with FGFR1-3 fusions or FGFR2 arrangements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) in participants with FGFR1-3 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of MRI biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with greater than 25% increase in MR regurgitant volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment failure, in terms of disease recurrence or death
Endpoint domain: Mortality/survival
Primary endpoint: Global improvement in IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantification of interferon-γ produced by specific CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of overall immune response by determination of the activity of CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of CMV viral replication in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Global Impression- Improvement scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Failures in using the Drive app
Endpoint domain: Adverse events/effects
Primary endpoint: Surface expression of functional biomarkers of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduced salt intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased level of physical exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regular compliance to medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMJ click and noises reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of electrical mechanical activation time (EMAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of acute bilirubin encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-inf) of MK-8931
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint position sense acuity of the wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-adjusted ACPR at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of lenalidomide with radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Engagement as measured by the number of log-ins into the web-based intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability as measured by participant's report of usefulness of each intervention module
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction as measured by participant's report on the Client Satisfaction Questionnaire (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Headpiece Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Headpiece Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbness and tingling
Endpoint domain: Adverse events/effects
Primary endpoint: Nail toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Increase in Absolute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PCI after TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-hospital and long-term clinical outcomes in patients undergoing PCI after TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline Corrected Insulin AUC0-360
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Corrected Insulin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Corrected Insulin Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physical exercise evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Hospitalized During the Test Period
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Days of Hospitalization During the Test Period
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Hospitalizations During the Test Period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in gastric acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with nasal shedding of influenza viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with oropharyngeal shedding of influenza viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Alexithymia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eating Disorder Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Endoscopic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean PG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net cost or savings per hospital day prevented
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Oxygen saturation after speaking aloud
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the severity of nasal SAR symptoms as assessed by Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of ocular SAR symptoms as assessed by Total Ocular Symptom Score (TOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the nasal obstruction using Peak Nasal Inspiratory Flow (PNIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Systemic Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: percentage change in iPTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Adequate Cytosponge™ Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with successful aneurysm treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of all cause mortality of TAA repair
Endpoint domain: Mortality/survival
Primary endpoint: Visual analogic Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plasma concentrations of etoposide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in functional bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Self-reported health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-reported pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in car restraint knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: knowledge, attitudes, and behaviors of healthcare workers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: S. aureus nasal carriage state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Accuracy of treatment/no treatment decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the Click Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost-effectiveness of the Click Device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with a measure of frailty prior to hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of frailty severity at hospital discharge with long term outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Need for Institutionalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Key image features of acute and chronic lung rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adverse clinical or paraclinical event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Children's Sleep Habits Questionnaire (CSHQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Complete closure at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in volume at first detrusor contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Plasma 9α-11β-PGF2 (9P) at 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma 9P at 20 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful implantation of left-heart lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications related to left-heart lead and delivery catheter
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-free progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Chest Compression Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct Compression Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes